O Polimorfismo no códon 98 do gene de galectina-3 não está associado a tumores benignos e malignos de tiróide
暂无分享,去创建一个
Luciane Martins | Suzana Garcia Leoni | Celso U. M. Friguglietti | Laura Sterian Ward | Marco Aurélio Vamondes Kulcsar | Edna Teruko Kimura | Edna Teruko Kimura | Luciane Martins | Suzana Garcia Leoni | Celso U. M. Friguglietti | Marco Aurélio Kulcsar | L. S. Ward | Marco Aurélio Vamondes Kulcsar
[1] A. Vecchione,et al. Application of an immunodiagnostic method for improving preoperative diagnosis of nodular thyroid lesions , 2001, The Lancet.
[2] M. Papotti,et al. Galectin-3: Presurgical marker of thyroid follicular epithelial cell-derived carcinomas , 2004, Journal of endocrinological investigation.
[3] S. Chanock,et al. SNPs in cancer research and treatment , 2004, British Journal of Cancer.
[4] T. Yoshii,et al. Galectin-3 maintains the transformed phenotype of thyroid papillary carcinoma cells. , 2001, International journal of oncology.
[5] S. Jeremiah,et al. Investigation of loss of heterozygosity and SNP frequencies in the RET gene in papillary thyroid carcinoma. , 2005, Thyroid : official journal of the American Thyroid Association.
[6] A. Rademaker,et al. TGFBR1*6A and cancer risk: a meta-analysis of seven case-control studies. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] J. Thompson,et al. The CLUSTAL_X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools. , 1997, Nucleic acids research.
[8] Y. Honjo,et al. The NH2 terminus of galectin-3 governs cellular compartmentalization and functions in cancer cells. , 1999, Cancer research.
[9] L. Ward,et al. Proline homozygosity in codon 72 of p53 is a factor of susceptibility for thyroid cancer. , 2004, Cancer letters.
[10] R. Lotan,et al. Differential expression of galectin-1 and galectin-3 in thyroid tumors. Potential diagnostic implications. , 1995, The American journal of pathology.
[11] W. Foulkes,et al. Risk of non-medullary thyroid cancer influenced by polymorphic variation in the thyroglobulin gene. , 2003, Carcinogenesis.
[12] T. Yoshii,et al. Expression of galectin‐3 in fine‐needle aspirates as a diagnostic marker differentiating benign from malignant thyroid neoplasms , 1999, Cancer.
[13] E. Kimura,et al. Galectin-3 messenger ribonucleic acid and protein are expressed in benign thyroid tumors. , 2002, The Journal of clinical endocrinology and metabolism.
[14] G. Fontanini,et al. Thyroid papillary carcinoma: preliminary evidence for a germ-line single nucleotide polymorphism in the Fas gene. , 2004, The Journal of endocrinology.
[15] Thomas L. Madden,et al. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. , 1997, Nucleic acids research.
[16] A. Longatto-Filho,et al. Differential reactivity for galectin-3 in Hürthle cell adenomas and carcinomas , 2001, Endocrine pathology.
[17] John L. Wang,et al. Intracellular functions of galectins. , 2002, Biochimica et biophysica acta.
[18] Douglas N W Cooper,et al. Galectinomics: finding themes in complexity. , 2002, Biochimica et biophysica acta.
[19] G. Heinze,et al. Polymorphisms in exon 13 and intron 14 of the RET protooncogene: genetic modifiers of medullary thyroid carcinoma? , 2005, The Journal of clinical endocrinology and metabolism.